Why this governance shift at PROCEPT BioRobotics matters for investors
A fresh investor lawsuit and the appointment of cardiac surgeon Dr. Michael Mack to the board put PROCEPT BioRobotics (PRCT) under a governance spotlight that stockholders will want to understand closely.
Recent trading tells a story of pressure rather than momentum for PROCEPT BioRobotics, with the share price delivering a 30 day return of down 21.31% and a year to date share price return of down 41.77%. The 1 year total shareholder return declined 48.46%, setting a weak backdrop for governance headlines and the fresh securities lawsuit.
Broaden your watchlist beyond PROCEPT BioRobotics by reviewing 31 resilient stocks with low risk scores that have been hand-picked for stronger risk profiles and potentially steadier execution.
PROCEPT BioRobotics now trades about 25% below the average analyst target after a steep slide driven by lawsuit headlines and governance concerns. Is that discount compensation for real risk, or a sign the market is overreacting?
Most Popular Narrative: 70.2% Undervalued
At a last close of $17.91, the most followed narrative on PROCEPT BioRobotics pegs fair value far higher at $60, which creates a sharp gap that investors are trying to explain.
I have been an investor in PRCT since before IPO. The wild fluctuations in share price recently make no sense. The sell side analyst who chased the share price up to highs in 2024 (when the price was way too frothy) are doing the same thing now by revising the share price lower and lower, when clearly the company is still doing a great job. The recent downgrade by Leerink, citing PAE as a possible headwind for PRCT growth, is in direct opposition to what Larry Wood (CEO) stated at the last earnings call. To quote Larry Wood, "I don't think PAE is a headwind for us at all. I think PAE is a big red herring. It's a procedure that really does not get performed in any volume in Europe. And the reason it doesn't get performed is because it doesn't get paid for because it's not a very good procedure." So if you believe Larry Wood, then the company has been grossly oversold and looks very very cheap down here. If PRCT hit the Q2 numbers watch all the sheep suddenly revise their target prices back up again. I think fair value is still up at $47. PRCT had a reassessment of how to report handpiece sales versus procedures and therefore there was a shortfall on revenue. Clearly they could have stuck with the old model and revenue would have been better. Larry is doing a great job of making reporting a direct reflection of procedures being done. If the numbers are delivered, watch this thing fly.
See why 6 investors see PROCEPT BioRobotics as 70% undervalued .
Result: Fair Value of $60 (UNDERVALUED)
Still, PROCEPT BioRobotics carries clear pressure points, including ongoing net losses and the risk that fresh litigation or board scrutiny could further dampen investor confidence.
Find out about the key risks to this PROCEPT BioRobotics narrative .
Another view on PROCEPT BioRobotics valuation
The narrative fair value on PROCEPT BioRobotics points to a large upside, yet the SWS DCF model tells a different story. At $17.91, the share price sits above an estimated future cash flow value of $16.64, which frames the stock as overvalued on this lens. Which signal should carry more weight for you?
For readers who want to unpack how this cash flow view is built in detail, Look into how the SWS DCF model arrives at its fair value.
Next Steps
Unsure whether the current sentiment around PROCEPT BioRobotics is too pessimistic or not cautious enough and want to form your own view quickly? Weigh both sides of the story by reviewing the 1 key reward and 1 important warning sign .
Looking for more investment ideas beyond PROCEPT BioRobotics?
If PROCEPT BioRobotics has sharpened your thinking, do not stop here. Fresh ideas from high quality screeners can shift your entire opportunity set.
-
Target resilient compounding potential by reviewing a list of solid balance sheet and fundamentals (25 results) that prioritises financial strength when markets turn choppy.
-
Hunt for mispriced quality and scan the 20 high quality undiscovered gems that many investors have not yet considered.
-
Dial up your focus on entry price and sift through the 29 high quality undervalued stocks before the crowd catches on.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PRCT .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
